Spink prepares UK launch for arthritis relief

Spink Consumer Relations is gearing up for the UK launch of Litozin, touting the product as a 'breakthrough' for joint pain and osteoarthritis sufferers.

The treatment, discovered in Denmark and popular in Scandinavia, is being marketed and distributed in the UK by GR Lane Health Products.

Spink is now handling a six-month UK launch campaign and has rented an apartment in central London where it will showcase Litozin to consumer journalists this Thursday.

An ongoing 'comprehensive' media relations campaign will target consumer journalists, while Spink will bid to secure 'tie-ups' with relevant patient groups.

Litozin, made by Danish firm Dansk Droge, is a clinically studied botanical extract that studies indicate can increase mobility in osteoarthritis patients and cut their need for traditional painkillers.

Agency director Jo Spink said: 'Litozin presents us with a real challenge in such a crowded market. But the clinical evidence for it is extremely positive.'

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in